Search Within

Thoracic Oncology

Formats
  1. Meeting Abstract (1709)
  2. Journal Article (1439)
  3. Review (82)
  4. Editorial (58)
  5. Book Section (35)
  6. Guidelines (25)
  7. Conference Paper (21)
  8. Correspondence (10)
  9. Research Letter (7)
  10. Miscellaneous (6)
  11. Book Whole (2)
Groups
  1. Department of Medicine (3394)
  2. Solid Tumor Oncology Division (3394)
  3. GSK Faculty (1071)
  4. Department of Pathology and Laboratory Medicine (809)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (662)
  6. Human Oncology and Pathogenesis Program (635)

More Groups

People
  1. Mark Kris (872)
  2. Alexander Drilon (637)
  3. Gregory Riely (605)
  4. Charles Rudin (495)
  5. Marc Ladanyi (418)
  6. Matthew Hellmann (412)

More People

Years
  1. 2025 (114)
  2. 2024 (271)
  3. 2023 (273)
  4. 2022 (337)
  5. 2021 (337)
  6. 2020 (258)

More Years

Publications
  1. Journal of Clinical Oncology (703)
  2. Journal of Thoracic Oncology (517)
  3. Annals of Oncology (278)
  4. Clinical Cancer Research (158)
  5. Cancer Research (128)
  6. International Journal of Radiation Oncology, Biology, Physics (89)

More Publications

Publishers
  1. American Society of Clinical Oncology (782)
  2. Elsevier Inc. (738)
  3. American Association for Cancer Research (386)
  4. Oxford University Press (352)
  5. Nature Publishing Group (156)
  6. Elsevier Science, Inc. (79)

More Publishers

Results (3394)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Chemotherapy definitions and policies for thymic malignancies
    Journal Article

    Girard, N.; Lal, R.; Wakelee, H.; Riely, G. J.; Loehrer, P. J.
    Chinese Journal of Lung Cancer (2014)

    Fulltext@MSK | Save
  • Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC)
    Journal Article

    Fury, M. G.; Sherman, E. J.; Rao, S. S.; Wolden, S.; Smith-Marrone, S.; Mueller, B.; Ng, K. K.; Dutta, P. R.; Gelblum, D. Y.; Lee, J. L.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing
    Journal Article

    Yu, H. A.; Arcila, M. E.; Hellmann, M. D.; Kris, M. G.; Ladanyi, M.; Riely, G. J.
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: A multicentre, open-label, phase 2 trial
    Journal Article

    Rajan, A.; Carter, C. A.; Berman, A.; Cao, L.; Kelly, R. J.; Thomas, A.; Khozin, S.; Chavez, A. L.; Bergagnini, I.; Scepura, B.; more...
    Lancet Oncology (2014)

    Fulltext@MSK | Save
  • Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC
    Journal Article

    Ou, S. H. I.; Jänne, P. A.; Bartlett, C. H.; Tang, Y.; Kim, D. W.; Otterson, G. A.; Crinò, L.; Selaru, P.; Cohen, D. P.; Clark, J. W.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Unsuspected collision of synchronous lung adenocarcinomas: A potential cause of aberrant driver mutation profiles
    Journal Article

    Rekhtman, N.; Borsu, L.; Reva, B.; Arcila, M.; Riely, G. J.; Ladanyi, M.; Drilon, A.
    Journal of Thoracic Oncology (2014)

    Fulltext@MSK | Save
  • Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: Proposal for the use of major pathological response as a surrogate endpoint
    Journal Article

    Hellmann, M. D.; Chaft, J. E.; William, W. N.; Rusch, V.; Pisters, K. M. W.; Kalhor, N.; Pataer, A.; Travis, W. D.; Swisher, S. G.; Kris, M. G.
    Lancet Oncology (2014)

    Fulltext@MSK | Save
  • Comparison of the characteristics and clinical course of 677 patients with metastatic lung cancers with mutations in KRAS codons 12 and 13
    Meeting Abstract

    Yu, H. A.; Sima, C. S.; Shen, R. L.; Kass, S. L.; Kris, M. G.; Ladanyi, M.; Riely, G. J.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK-positive non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Solomon, B. J.; Gettinger, S. N.; Riely, G. J.; Gadgeel, S. M.; Nokihara, H.; Han, J. Y.; Hida, T.; Satouchi, M.; Baldini, E.; Siena, S.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Response to erlotinib and prognosis for patients with de novo epidermal growth factor receptor (EGFR) T790M mutations
    Meeting Abstract

    Riely, G. J.; Yu, H. A.; Arcila, M. E.; Hellmann, M. D.; Ladanyi, M.; Kris, M. G.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save